Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more) Laser Photonics Reports Full Year Total Net Sales Increase of 144% in Q4 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

LadRx Corporation (EM) LADX

Healthcare Biotechnology
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, Calif...


EXPM:LADX - Post by User

LadRx Corporation (EM)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
  • samantha231X
Post by samantha231on Mar 27, 2014 2:24pm
466 Views
Post# 22377404

CYTR and ICLD have same lies from blog seekingalpha

CYTR and ICLD have same lies from blog seekingalphaJust to advise you that CYTR and ICLD have exactly the same lawsuits being filed against them and all stemming from the blogger seekingalpha.com.
Exactly the same law firms are involved in both companies and for the exact same reasons in both cases 'that the prices were inflated by the Dream Team'. Both companies have explanations that are carbon copies of each other with same legal coucil for both..
These tactics have driven down both stocks and someone is definitely cashing in.  
I will definitely be looking into filing complaints against seekingalpha.com and their associates for possibly their own security fraud. Their claims against two companies is the key. Perhaps when investigated, shareholders shld be in litigation in seeking damages against the blogger.

I am still invested in CYTR. good luck.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities